Phase IIIb data backs Daiichi Sankyo's Lixiana in atrial fibrillation patients undergoing cardioversion
Japanese drug major Daiichi Sankyo (TYO: 4568) has announced results from the global Phase IIIb ENSURE-AF study of Lixiana (edoxaban) in patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion.
Data demonstrated that the oral, once-daily drug, which is known as Savaysa in the USA, met the study’s primary endpoints, showing comparable efficacy and safety to well-managed enoxaparin/warfarin for the prevention of stroke and other blood clot complications.
The results from ENSURE-AF were presented on Tuesday at the European Society of Cardiology (ESC) Congress 2016 in Rome, and published in The Lancet. They show that Lixiana may be an effective and well-tolerated alternative to conventional treatment with enoxaparin and a vitamin K antagonist (VKA), and may allow prompt cardioversion to be performed with transoesophageal echocardiography (TEE)
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze